Him & Hers Health Stock Soars After Cheap Weight-Loss Drug Offering

On Monday, Him & Hers formally announced that it would provide access to GLP-1 injections to its users. Moreover, it would look to pass the savings onto its customers. That gives its customers “an affordable way to consistently access safe, high-quality weight loss treatment”.
Customers will be able to access weight-loss treatments with the same active ingredient as Ozempic and Wegovy.

The pricing for these weight loss medications will start as low as $79 per month for oral medications and $199 per month for compounded GLP-1 injections.

Him & Hers Health last unveiled its first quarter (Q1) fiscal 2024 earnings on May 6, 2024. It reported revenue growth of 46% year-over-year to $278 million. Meanwhile, it posted net income of $11.1 million – up from a net loss of $10.1 million in Q1 fiscal 2023. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. This company delivered adjusted EBITDA of $32.3 million – up from $6.1 million in the previous year.

This company currently possesses an immaculate balance sheet, and its stock is still trading in favourable value territory. Him & Hers foray into the gigantic weight-loss drug market holds huge potential going forward.